Literature DB >> 8604239

Inhibitory effect of alkane-6,8-diols, the components of safflower, on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.

K Yasukawa1, T Akihisa, Y Kasahara, T Kaminaga, H Kanno, K Kumaki, T Tamura, M Takido.   

Abstract

Erythro-alkane-6,8-diols were isolated from the flowers of Carthamus tinctorius. 12-0-Tetradecanoylphorbol-13-acetate (TPA, 1 microgram/ear), a tumor-promoting agent, was applied to the ears of mice to induce inflammation. Of 8 alkane-6,8-diols assayed, the C27, C31, C32, C33 and C35 alkane diols inhibited the inflammation. The 50% inhibitory dose of these compounds for TPA-induced inflammation was 0.5-0.7 mg/ear. However, C21, C23 and C25 alkane-6,8-diols were found to have no effect. Furthermore, the mixture of erythro-alkane-6,8-diols from the flowers of C. tinctorius markedly suppressed the promoting effect of TPA on skin tumor formation in mice following initiation with 7,12-dimethylbenz[a]anthracene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604239     DOI: 10.1159/000227549

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Antioxidant and neuroprotective activities of Mogami-benibana (safflower, Carthamus tinctorius Linne).

Authors:  Midori Hiramatsu; Tomoko Takahashi; Makiko Komatsu; Toshitaka Kido; Yoshimasa Kasahara
Journal:  Neurochem Res       Date:  2008-12-12       Impact factor: 3.996

Review 2.  Medical uses of Carthamus tinctorius L. (Safflower): a comprehensive review from Traditional Medicine to Modern Medicine.

Authors:  Elahe Delshad; Mahdi Yousefi; Payam Sasannezhad; Hasan Rakhshandeh; Zahra Ayati
Journal:  Electron Physician       Date:  2018-04-25

3.  Carthamus tinctorius Enhances the Antitumor Activity of Dendritic Cell Vaccines via Polarization toward Th1 Cytokines and Increase of Cytotoxic T Lymphocytes.

Authors:  Jia-Ming Chang; Le-Mei Hung; Yau-Jan Chyan; Chun-Ming Cheng; Rey-Yuh Wu
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-03       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.